Bicycle Therapeutics plc
BCYC
$7.12
$0.020.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.28M | 25.72M | 35.28M | 36.90M | 39.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.28M | 25.72M | 35.28M | 36.90M | 39.57M |
| Cost of Revenue | 113.13M | 82.16M | 57.83M | 169.81M | 162.33M |
| Gross Profit | -90.14M | -52.73M | -18.85M | -132.91M | -122.76M |
| SG&A Expenses | 77.58M | 75.03M | 70.42M | 63.53M | 60.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 307.60M | 274.08M | 245.15M | 233.34M | 222.97M |
| Operating Income | -288.32M | -248.36M | -209.87M | -196.44M | -183.40M |
| Income Before Tax | -248.21M | -208.72M | -173.80M | -169.64M | -163.02M |
| Income Tax Expenses | -5.85M | -5.50M | -4.77M | -3.36M | 2.36M |
| Earnings from Continuing Operations | -242.36 | -203.22 | -169.03 | -166.28 | -165.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -242.36M | -203.22M | -169.03M | -166.28M | -165.37M |
| EBIT | -288.32M | -248.36M | -209.87M | -196.44M | -183.40M |
| EBITDA | -281.11M | -241.21M | -202.70M | -189.32M | -176.75M |
| EPS Basic | -3.51 | -3.13 | -2.88 | -3.28 | -3.81 |
| Normalized Basic EPS | -2.28 | -2.04 | -1.87 | -2.07 | -2.34 |
| EPS Diluted | -3.51 | -3.13 | -2.88 | -3.28 | -3.81 |
| Normalized Diluted EPS | -2.28 | -2.04 | -1.87 | -2.07 | -2.34 |
| Average Basic Shares Outstanding | 276.49M | 259.23M | 232.59M | 205.96M | 176.55M |
| Average Diluted Shares Outstanding | 276.49M | 259.23M | 232.59M | 205.96M | 176.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |